Skip to main content
. 2024 Jan 13;16(2):340. doi: 10.3390/cancers16020340

Figure 4.

Figure 4

Overall incidence of vitiligo by drug class groupings via fixed-effect modeling of 31 studies reporting vitiligo. Incidence of vitiligo was highest in the IO combination (10.1%) and PD-1 monotherapy (7.9%) groups, followed by the IO + chemotherapy (3.7%), CTLA-4 monotherapy (3.2%), and PD-L1 monotherapy (0.54%) groups. No studies on IO + antiangiogenic combination regimens reported vitiligo [17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190].